NGBiLab S3.E16: Cerebro Therapeutics
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
NGBiLab S3.E16: Cerebro Therapeutics
-
ナレーター：
-
著者：
Cerebro Therapeutics is a biotech company based in Quebec City developing disease-modifying treatments for neurodegenerative disorders, with a primary focus on Parkinson's.
Unlike current therapies that only manage symptoms, Cerebro is working to stop the disease from progressing altogether.
In this episode, Jim Wilson speaks with president and co-founder Martin Levesque about a company that spun directly out of his research lab at Laval University.
Martin explains the science behind their approach, which combines immunotherapy and gene therapy to deliver protective antibodies across the blood-brain barrier in a single injection, and how a striking result in a mouse model convinced him the work needed to reach patients.
Martin also reflects on the leap from academic researcher to startup founder, the support of the Michael J. Fox Foundation, and why he believes the first treatment to halt Parkinson's could be made in Canada.